BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2023 9:36:12 AM | Browse: 72 | Download: 220
 |
Received |
|
2023-09-21 13:29 |
|
Peer-Review Started |
|
2023-09-21 13:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-10-10 08:48 |
|
Revised |
|
2023-10-20 11:50 |
|
Second Decision |
|
2023-11-14 01:15 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-11-17 08:49 |
|
Articles in Press |
|
2023-11-17 08:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-11-13 02:53 |
|
Typeset the Manuscript |
|
2023-12-08 03:44 |
|
Publish the Manuscript Online |
|
2023-12-14 09:36 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Basic Study |
| Article Title |
Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1a and inhibiting the RhoA/ROCK pathway
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Na Li, Qiu-Xiao Zhu, Gui-Zhi Li, Ting Wang and Hong Zhou |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Health Commission of Hebei Province |
20210196 |
| S＆T Program of Hebei |
22377726D |
|
| Corresponding Author |
Hong Zhou, PhD, Chief Physician, Doctor, Department of Endocrinology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang 050000, Hebei Province, China. zhoubs2013@163.com |
| Key Words |
Empagliflozin; Diabetic cardiomyopathy; AMPK; ROCK; Apoptosis; Oxidative stress |
| Core Tip |
We established a diabetic cardiomyopathy model in db/db mice and treated the mice with empagliflozin for 8 wk, and found that empagliflozin observably improved cardiac function in diabetic mice, which was maybe related to activation of AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1a) and inhibition of the RhoA/ROCK pathway. In order to exclude the effects of metabolic improvement on the heart in vivo, in vitro experiment in high glucose conditions was performed. The results confirmed that the anti-oxidative stress and anti-apoptotic effects of empagliflozin on cardiomyocytes were achieved by activating AMPK/PGC-1a and inhibiting ROCK. Furthermore, the effects were independent of sodium-glucose cotransporter (SGLT)2 inhibition as no SGLT2 expression was detected on cardiomyocytes. |
| Publish Date |
2023-12-14 09:36 |
| Citation |
Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1 and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; I14(12): 1862-1876 |
| URL |
https://www.wjgnet.com/1948-9358/full/v14/i12/1862.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v14.i12.1862 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
